InMed Pharmaceuticals Achieves 2g/L Cannabinoid Yield with IntegraSyn™
April 26 2021 - 7:30AM
InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (Nasdaq: INM;
TSX:IN), a clinical-stage company developing cannabinoid-based
pharmaceutical drug candidates and leading the clinical development
of cannabinol (“CBN”), today announced that its IntegraSyn™
cannabinoid manufacturing approach has achieved a level of 2g/L
cannabinoid yield, a milestone that signals commercial viability
and supports advancement to large-scale production in the coming
months.
For its first application using the IntegraSyn™ approach, InMed
set two main objectives to enable a cost-effective solution to
cannabinoid production: to achieve a commercially viable yield
higher than current industry standards and to lower overall
manufacturing costs through process optimization. InMed’s
IntegraSyn™ manufacturing approach was able to achieve both
objectives. IntegraSyn™ utilizes an enzymatic biotransformation
process as a part of an overall integrated cannabinoid
manufacturing approach to overcome certain natural yield
limitations of traditional biosynthesis for full cannabinoid
assembly. Having achieved a 2g/L yield level, InMed will now focus
on manufacturing scale-up to larger batch sizes while continuing
process and enzyme optimization, targeting increased cannabinoid
yield and further reducing the overall cost of goods. In parallel,
the Company continues to prepare the manufacturing process to be
Good Manufacturing Practice (GMP)-ready for pharmaceutical quality
production. The next stage of large-scale production is to produce
a batch with a target output of one kilogram of the selected
cannabinoid in 2H2021 via a GMP-ready process.
“We are very pleased to have achieved this high yield at this
stage and are looking forward to applying the IntegraSyn™ approach
to large-scale production. As this scale-up progresses, we will
also seek to further optimize our manufacturing and purification
processes and further enhance the enzyme design. These ongoing
improvements will focus on achieving even higher yields, beyond the
already impressive 2g/L,” commented Eric Hsu, Senior Vice
President, Preclinical R&D. “I would also like to acknowledge
the Almac Group, our collaborator and contract manufacturing
partner, for bringing their extensive knowledge and expertise to
the program as we reached this important milestone.”
Michael Woudenberg, Vice President of Chemistry, Manufacturing
and Controls, added, “In addition to achieving a commercially
viable cannabinoid yield level, we have focused on utilizing
cost-competitive starting materials to enable a cost-effective
solution to pharmaceutical-grade cannabinoid production with
IntegraSyn™. We believe this is especially important in accessing
rare cannabinoids.”
About InMed: InMed Pharmaceuticals is a
clinical-stage company developing a pipeline of cannabinoid-based
pharmaceutical drug candidates, initially focused on the
therapeutic benefits of cannabinol (“CBN”), in diseases with high
unmet medical need. The Company is dedicated to delivering new
therapeutic alternatives to patients that may benefit from
cannabinoid-based pharmaceutical drugs. For more information, visit
www.inmedpharma.com.
About IntegraSyn™: IntegraSyn™ is InMed's
integrated cannabinoid manufacturing system designed to efficiently
and economically produce pharmaceutical-grade, bio-identical
cannabinoids. The scalable and flexible IntegraSyn™ manufacturing
system integrates multiple commercially proven methods to
efficiently produce cannabinoids utilizing cost-effective
processes.
About Almac Group: The Almac Group is an
established contract development and manufacturing organization
providing an extensive range of integrated services across the drug
development lifecycle to the pharmaceutical and biotech sectors
globally. Its innovative services range from R&D, biomarker
discovery development and commercialization, API manufacture,
formulation development, clinical trial supply, Interactive
Response Technology through to commercial-scale manufacture. Almac
is an international, privately-owned organization which has grown
organically over the past five decades now employing over 5,600
highly skilled personnel across 18 facilities including Europe, the
US and Asia. For more information please visit almacgroup.com.
Investor
Contact: Edison GroupJoe Green/Laine YonkerT:
+1.646.653.7030/+1.646.653.7035E: jgreen@edisongroup.com
lyonker@edisongroup.com |
Cautionary Note Regarding Forward-Looking
Information:
Cautionary Note Regarding Forward-Looking Information: This news
release contains "forward-looking information" and "forward-looking
statements" (collectively, "forward-looking information") within
the meaning of applicable securities laws. Forward-looking
information is based on management's current expectations and
beliefs and is subject to a number of risks and uncertainties that
could cause actual results to differ materially from those
described in the forward-looking statements. Forward-looking
information in this news release includes statements about:
commercial viability and advancement to large-scale production and
the timing thereof; the focus of the Company on manufacturing
scale-up to larger batch sizes while continuing process and enzyme
optimization, targeting increased cannabinoid yield and reducing
overall costs; the preparation to be GMP-ready; IntegraSyn™ being
able to efficiently and economically produce pharmaceutical-grade,
bio-identical cannabinoids; delivering new therapeutic alternatives
to patients that may benefit from cannabinoid-based pharmaceutical
drugs; and the next stage being a target output of one kilogram of
the selected cannabinoid in 2H2021 via a GMP-ready process. With
respect to the forward-looking information contained in this news
release, InMed has made numerous assumptions regarding, among other
things: that the manufacturing approach means commercial viability
and possible large-scale production; cannabinoid yield can be
increased; overall costs can be reduced; the manufacturing process
is possible to be GMP-ready for pharmaceutical quality production;
and optimization of the manufacturing and purification processes
and further enhancement of enzyme design is possible. While InMed
considers these assumptions to be reasonable, these assumptions are
inherently subject to significant business, economic, competitive,
market and social uncertainties and contingencies. Additionally,
there are known and unknown risk factors which could cause InMed’s
actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking information contained
herein. Known risk factors include, among others: the outbreak and
impact of COVID-19 may worsen; commercial viability and large-scale
production may not be possible within anticipated timelines or at
all; the manufacturing process may not be GMP-ready for
pharmaceutical quality production; demand or interest for InMed's
products may decrease or cease; and economic and market conditions
may become unstable or unfavorable. A more complete discussion of
the risks and uncertainties facing InMed is disclosed in InMed’s
filings with the Securities and Exchange Commission and the most
recent Annual Information Form filed with Canadian securities
regulatory authorities on SEDAR at www.sedar.com. All
forward-looking information herein is qualified in its entirety by
this cautionary statement, and InMed disclaims any obligation to
revise or update any such forward-looking information or to
publicly announce the result of any revisions to any of the
forward-looking information contained herein to reflect future
results, events or developments, except as required by law.
NEITHER THE TORONTO STOCK EXCHANGE NOR ITS REGULATIONS SERVICES
PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR
ACCURACY OF THIS RELEASE.
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Aug 2024 to Sep 2024
InMed Pharmaceuticals (NASDAQ:INM)
Historical Stock Chart
From Sep 2023 to Sep 2024